Compare AbCellera Biologics Inc (ABCL) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Devon Energy Corp — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Devon Energy Corp trades at $42.95 (market cap $48.92B). The key difference: Devon Energy Corp is far larger — about 20.8× AbCellera Biologics Inc's market cap, and Devon Energy Corp pays a 2.45% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DVN | |
|---|---|---|
Market Cap | $2.35B | $48.92B |
Sector | Health | Energy |
52-Week High | $8.12 | $52.07 |
52-Week Low | $2.78 | $31.74 |
Enterprise Value | $1.99B | $55.69B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Devon Energy (DVN) trades at $42.41, up 4.79% on the day, with a bearish technical signal but bullish oscillators. The stock shows strong profitability with a 13.71% net margin and trades at a P/E of 11.24, below sector averages. Recent news highlights activist pressure for asset sales and a pending Q2 2026 earnings report on August 4, 2026.
DVN presents a value opportunity with a consensus price target of $61.60, implying 45% upside, supported by a 71% buy rating from analysts. Risks include oil price volatility, execution of the Coterra merger synergies, and activist investor demands. The company's disciplined capital allocation and strong cash flow generation underpin the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
